Bioanalytical Community

 View Only

New AAPS Journal article of possible community interest

  • 1.  New AAPS Journal article of possible community interest

    Posted 07-11-2023 10:52
    Multifaceted approach for quantification and enzymatic activity of Iduronate-2-sulfatase to support developing gene therapy for Hunter Syndrome

    Mucopolysaccharidosis type II, commonly called Hunter syndrome, is a rare X-linked recessive disease caused by the deficiency of the lysosomal enzyme iduronate-2-sulphatase (I2S). A deficiency of I2S causes an abnormal glycosaminoglycans accumulation in the body's cells. Although enzyme replacement therapy is the standard therapy, adeno-associated viruses (AAV)–based gene therapy could provide a single-dose solution to achieve a prolonged and constant enzyme level to improve patient's quality of life. Currently, there is no integrated regulatory guidance to describe the bioanalytical assay strategy to support gene therapy products. Herein, we describe the streamlined strategy to validate/qualify the transgene protein and its enzymatic activity assays. The method validation for the I2S quantification in serum and method qualification in tissues was performed to support the mouse GLP toxicological study. Standard curves for I2S quantification ranged from 2.00 to 50.0 μg/mL in serum and 6.25 to 400 ng/mL in the surrogate matrix. Acceptable precision, accuracy, and parallelism in the tissues were demonstrated. To assess the function of the transgene protein, fit-for-purpose method qualification for the I2S enzyme activity in serum was performed. The observed data indicated that the enzymatic activity in serum increased dose-dependently in the lower I2S concentration range. The highest I2S transgene protein was observed in the liver among tissue measured, and its expression level was maintained up to 91 days after the administration of rAAV8 with a codon-optimized human I2S. In conclusion, the multifaceted bioanalytical method for I2S and its enzymatic activity were established to assess gene therapy products in Hunter syndrome.

    To view the full article through your AAPS membership:

    Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal. Click or tap if you trust this link." rel="noopener">https://www.aaps.org/education-and-research/journals/the-aaps-journal 

    Enter your AAPS credentials

    Click "Member Access to Journals"

    Click on the The AAPS Journal cover.

    Copy and paste the url into the "Search" box, and click search

    The full article should appear.

    Follow The AAPS Journal via Twitter: https://twitter.com/theaapsjournal

    and by Linkedin,  https://www.linkedin.com/showcase/theaapsjournal/



    ------------------------------
    Ho-Leung Fung Ph.D., FAAPS
    Editor-in-Chief
    University at Buffalo
    Sarasota FL
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------